QIAGEN计划进行300M合成股份回购,以便在2025年年中前提高股东价值。 QIAGEN plans a $300M synthetic share repurchase to enhance shareholder value by mid-2025.

荷兰生命科学公司QIAGEN N.V.计划通过合成股份回购向股东返还约3亿美元,以提高股东价值和优化其资本结构。 QIAGEN N.V., a Dutch life sciences firm, plans to return about $300 million to shareholders via a synthetic share repurchase, aiming to enhance shareholder value and optimize its capital structure. 这种回购将涉及发行新股票,为国库投资提供资金,并分阶段购回股票。 The repurchase will involve issuing new shares, funding a treasury investment, and buying back shares in stages. 预计到2025年中期完成,等待市场条件和监管批准。 Completion is expected by mid-2025, pending market conditions and regulatory approvals.